Compare · IQV vs NOTV
IQV vs NOTV
Side-by-side comparison of IQVIA Holdings Inc. (IQV) and Inotiv Inc. (NOTV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IQV and NOTV operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- IQV is the larger of the two at $42.70B, about 15318.2x NOTV ($2.8M).
- IQV has hit the wire 6 times in the past 4 weeks while NOTV has been quiet.
- IQV has more recent analyst coverage (25 ratings vs 9 for NOTV).
- Company
- IQVIA Holdings Inc.
- Inotiv Inc.
- Price
- -
- -
- Market cap
- $42.70B
- $2.8M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NYSE
- NASDAQ
- IPO
- 2013
- News (4w)
- 6
- 0
- Recent ratings
- 25
- 9
IQVIA Holdings Inc.
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Inotiv Inc.
Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It has an agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.
Latest IQV
- IQVIA's AI-Enabled Clinical Decision Support Tool Wins 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year
- IQVIA Ranked No. 1 Pharmaceutical Technology Provider by Everest Group
- Officer Staub W Richard sold $1,279,740 worth of shares (5,500 units at $232.68), decreasing direct ownership by 29% to 13,312 units (SEC Form 4)
- Officer Patel Bhavik sold $436,426 worth of shares (1,855 units at $235.27), decreasing direct ownership by 58% to 1,348 units (SEC Form 4)
- IQVIA and Medera to Advance Cardiac Gene Therapy and Human-Based Drug Discovery
- SEC Form 144 filed by IQVIA Holdings Inc.
- Officer Sherbet Eric sold $1,245,800 worth of shares (5,000 units at $249.16), decreasing direct ownership by 19% to 20,999 units (SEC Form 4)
- Officer Cherofsky Keriann sold $136,827 worth of shares (558 units at $245.21), decreasing direct ownership by 16% to 2,989 units (SEC Form 4)
- Officer Bousbib Ari exercised 156,206 shares at a strike of $78.21, sold $26,092,072 worth of shares (106,279 units at $245.51) and returned $12,217,110 worth of shares to the company (49,927 units at $244.70) (SEC Form 4)
- SEC Form 144 filed by IQVIA Holdings Inc.
Latest NOTV
- SEC Form 15-12G filed by Inotiv Inc.
- SEC Form 8-K15D5 filed by Inotiv Inc.
- SEC Form EFFECT filed by Inotiv Inc.
- SEC Form EFFECT filed by Inotiv Inc.
- SEC Form EFFECT filed by Inotiv Inc.
- Director Brown Nigel disposed of 104,929 shares, closing all direct ownership in the company (SEC Form 4)
- Chief Financial Officer Taylor Beth A. disposed of 139,616 shares, closing all direct ownership in the company (SEC Form 4)
- Chief Strategy Officer Sagartz John E disposed of 729,626 shares, closing all direct ownership in the company (SEC Form 4)
- Director Neff R Matthew disposed of 151,102 shares, closing all direct ownership in the company (SEC Form 4)
- Director Landman David disposed of 216,243 shares, closing all direct ownership in the company (SEC Form 4)